Apixaban for Routine Management of Upper Extremity Deep Venous Thrombosis

Inclusion Criteria: * Be ≥ 18 years of age * Have received no more than six (6) doses of any therapeutic anticoagulant, or intravenous and bridging heparin for longer than 72 hours * Women must not be breastfeeding * Receiving apixaban as administered per clinical routine (apixaban 10 mg by mouth twice daily for 7 days, followed by apixaban 5 mg twice daily for 11 weeks) * Provide informed consent within 72 hours of receiving apixaban Exclusion Criteria: * Another indication for long-term anticoagulation for which no FDA approval of apixaban exists (e.g. prosthetic heart valves) * Life expectancy of less than 6 months * Unable to engage in reliable follow-up as per protocol * Participating in a clinical trial or has participated in a clinical trial within the last 30 days * Receiving concomitant dual antiplatelet therapy * Requires aspirin dose of greater than 165 mg daily * Intend pregnancy or breastfeeding within the next year * Known allergy to apixaban, rivaroxaban, or edoxaban * Active pathological bleeding. * Any condition that at the discretion of the investigator is thought to prohibit active participation and follow-up in the trial * UEDVT that occurs while therapeutic anticoagulation is being taken by the patient ("event on therapy") * The patient has concomitant VTE diagnosed elsewhere except deep vein thrombosis that has its most proximal aspect in the distal veins ("isolated distal DVT") * Any contraindication to apixaban referenced in the package insert